Atriance 5 mg/ml solution for infusion * Pharmacy Only: Prescription
Company:
Novartis Ireland LimitedStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
This medicinal product is subject to additional monitoring.
*Additional information is available within the SPC or upon request to the company
Updated on 20 April 2023
File name
64414e33927f8.pdf
Reasons for updating
- Change to section 6 - manufacturer
Free text change information supplied by the pharmaceutical company
Inserted PF number in Title
Updated on 09 February 2023
File name
63e4df317a7d6.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 09 February 2023
File name
63e4d7ea55145.pdf
Reasons for updating
- Change to section 7 - Marketing authorisation holder
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 05 October 2021
File name
Atriance_REG PIL_IPHA_Sept2021_1633430746.pdf
Reasons for updating
- Change to section 6 - manufacturer
Updated on 10 November 2020
File name
Atriance_REGPIL PF20-0244_IPHA_1605007627.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
Updated on 10 November 2020
File name
Atriance_5mg-ml_REG SmPC_PF 20-0244_IPHA_1605007567.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 19 November 2019
File name
Atriance REG PIL_PF 19-0232_0247_IPHA_1574164187.pdf
Reasons for updating
- Change to section 4 - how to report a side effect
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
Updated on 18 November 2019
File name
Atriance_5mg-ml_REG SmPC_PF 19-0232_247_IPHA_1574092725.pdf
Reasons for updating
- Change to section 6.5 - Nature and contents of container
- Change to section 8 - Marketing authorisation number(s)
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 28 March 2019
File name
Atriance_5mg-ml_Soln_Inf_REGSmPC_PF 18-0109_May2018_IPHA_1553790500.pdf
Reasons for updating
- File format updated to PDF
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 15 October 2018
File name
Atriance REG PIL_62000000029914_R219_IPHA_1539596185.pdf
Reasons for updating
- Change to section 6 - marketing authorisation holder
Updated on 21 May 2018
File name
Atriance_5mg-ml_Soln_Inf_REGSmPC_PF 18-0109_May2018_clean.docx
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.8 - Undesirable effects
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 13 September 2017
File name
PIL_12579_265.pdf
Reasons for updating
- New PIL for new product
Updated on 13 September 2017
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Change to section 6 - what the product contains
Updated on 03 July 2017
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 03 July 2017
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 6.4 - Special precautions for storage
- Change to section 6.5 - Nature and contents of container
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 4.4 has new warnings added and section 4.8 has additional ADRs included.
Section 4.6 has been updated with advice to discontinue breast-feeding during treatment with Atriance.
Section 4.7 has been revised to include the statement: "Atriance has major influence on the ability to drive and use machines".
The storage conditions have been updated in section 6.4.
Section 6.6 has been revised to include the word "cytotoxic".
Updated on 25 May 2016
Reasons for updating
- Change to marketing authorisation holder
Updated on 20 January 2016
Reasons for updating
- Change to section 9 - Date of renewal of authorisation
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 02 June 2015
Reasons for updating
- Change to section 7 - Marketing authorisation holder
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
7. MARKETING AUTHORISATION HOLDER
Updated on 09 September 2013
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Atriance 5 mg/ml solution for infusion
EMEA/H/C/752/IAIN/20 - to add black triangle
Summary of changes for the SUMMARY OF PRODUCT CHARACTERISTICS
Addition of the black triangle at the top of the SPC:
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.
Addition of the following paragraph to section 4.8:
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.directly to the IMB (please see details below):
Pharmacovigilance Section
Irish Medicines Board
Kevin O’Malley House
Earlsfort Centre
Earlsfort Terrace
IRL - Dublin 2
Tel: +353 1 6764971
Fax: +353 1 6762517
Website: www.imb.ie
e-mail: imbpharmacovigilance@imb.ie
Summary of changes the for PACKAGE LEAFLET
An update to the following paragraph in section 4. Possible side effects
Addition of the black triangle at the top of the SPC:
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
Update to the opening paragraph:
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effect not listed in this leaflet. See section 4.
Addition of the following paragraph to section 4:
Reporting of side effects
If you get any of the side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.
Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard
Ireland
Pharmacovigilance Section
Irish Medicines Board
Kevin O’Malley House
Earlsfort Centre
Earlsfort Terrace
IRL - Dublin 2
Tel: +353 1 6764971
Fax: +353 1 6767836
Website: www.imb.ie
e-mail: imbpharmacovigilance@imb.ie
Updated on 30 August 2013
Reasons for updating
- Change to side-effects
Updated on 17 May 2013
Reasons for updating
- Change to section 7 - Marketing authorisation holder
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
SPC updates:
Update to Section 7. MARKETING AUTHORISATION HOLDER
From:
Glaxo Group Limited,
Berkeley Avenue,
Greenford,
Middlesex
UB6 0NN,
United Kingdom
To:
Glaxo Group Limited
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom
Updated on 16 May 2013
Reasons for updating
- Change to MA holder contact details
Updated on 09 November 2012
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 6.5 - Nature and contents of container
- Change to section 6.6 - Special precautions for disposal and other handling
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml of solution contains 5 mg of nelarabine.
Each vial contains 250 mg of nelarabine.
Excipient(s) with known effect:
eEach ml of solution contains 1.725 mg (75 micromols) of sodium.
4.2 Posology and method of administration
Complete blood counts including platelets must be monitored regularly (see sections 4.4 and 4.8).
Method of administration
Nelarabine is must not be diluted prior to administration. The appropriate dose of nelarabine is must be transferred into polyvinylchloride (PVC) or ethyl vinyl acetate (EVA) infusion bags or glass containers and administered intravenously as a two-hour infusion in adult patients and as a one-hour infusion in paediatric patients.
Complete blood counts including platelets must be monitored regularly (see sections 4.4 and 4.8).
4.4 Special warnings and precautions for use
NEUROLOGICAL ADVERSE Severe neurological reactions Full recovery from these |
4.8 Undesirable effects
|
||
|
||
|
||
Rhabdomyolysis, blood creatine phosphokinase increased (see Post – Marketing Data) |
Rare: N/A |
Rare: N/A |
|
Description of selected adverse reactions
Infection and Infestations
There was a single additional report of biopsy confirmed progressive multifocal leukoencephalopathy in the adult population.
There have been reports of sometimes fatal opportunistic infections in patients receiving nelarabine therapy.
Nervous System disorders
There have been reports of events associated with demyelination and ascending peripheral neuropathies similar in appearance to Guillain-Barré syndrome.
One subject in the paediatric group had a fatal neurological event of status epilepticus.
6.5 Nature and contents of container
Clear glass (Type I) vials with a non-latex bromobutyl rubber stopper, sealed with an aluminium cap.
6.6 Special precautions for disposal and other handling
— All items for administration or cleaning, including gloves, should be placed in high-risk, waste disposal bags for high-temperature incineration. Any lLiquid waste from the preparation of the nelarabine solution for infusion may be flushed with large amounts of water.
Updated on 07 November 2012
Reasons for updating
- Change to dosage and administration
Updated on 27 March 2012
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 4.8 - Undesirable effects
Updated on 27 March 2012
Reasons for updating
- Change to warnings or special precautions for use
Updated on 28 April 2011
Reasons for updating
- Change to warnings or special precautions for use
Updated on 22 February 2011
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
1. NAME OF THE MEDICINAL PRODUCT
Atriance 5 mg/ml solution for infusion
*********************************************************
4. CLINICAL PARTICULARS
4.2 Posology and method of administration
Nelarabine is for intravenous use only and must only be administered under the supervision of a physician experienced in the use of cytotoxic agents.
Posology
Patients receiving nelarabine are recommended to receive intravenous hydration according to standard medical practice for the management of hyperuricemia in patients at risk for tumour lysis syndrome. For patients at risk of hyperuricemia, the use of allopurinol should be considered (see section 4.4).
Nelarabine is not diluted prior to administration. The appropriate dose of nelarabine is transferred into polyvinylchloride (PVC) or ethyl vinyl acetate (EVA) infusion bags or glass containers and administered as a two-hour infusion in adult patients and as a one-hour infusion in paediatric patients.
Complete blood counts including platelets must be monitored regularly (see sections 4.4 and 4.8). Patients receiving nelarabine are recommended to receive intravenous hydration according to standard medical practice for the management of hyperuricemia in patients at risk for tumour lysis syndrome. For patients at risk of hyperuricemia, the use of allopurinol should be considered (see section 4.4).
Adults and adolescents (aged 16 years and older)
The recommended dose of nelarabine for adults is 1,500 mg/m2 administered intravenously over two hours on days 1, 3 and 5 and repeated every 21 days.
Paediatric population
Children and adolescents (aged 21 years and younger)
The recommended dose of nelarabine for children is 650 mg/m2 administered intravenously over one hour daily for 5 consecutive days, repeated every 21 days.
In clinical studies, the 650 mg/m2 and 1,500 mg/m2 dose have both been used in patients in the age range 16 to 21 years. Efficacy and safety were similar for both regimens. The prescribing physician should consider which regimen is appropriate when treating patients in this age range. Limited clinical pharmacology data are available for patients below the age of 4 years (see section 5.2).
Dose modification
Nelarabine must be discontinued at the first sign of neurological events of National Cancer Institute Common Terminology Criteria Adverse Event (NCI CTCAE) grade 2 or greater. Delaying subsequent dosing is an option for other toxicities, including haematological toxicity.
Elderly
Insufficient numbers of patients aged 65 years of age and older have been treated with nelarabine to determine whether they respond differently than younger patients (see sections 4.4 and 5.2).
Renal Impairment
Nelarabine has not been studied in individuals with renal impairment. Nelarabine and 9-β-D-arabinofuranosylguanine (ara-G) are partially renally excreted (see section 5.2 — Renal impairment). There are insufficient data to support a dose adjustment recommendation for patients with a renal clearance of creatinin Clcr less than 50 ml/min. Patients with renal impairment must be closely monitored for toxicities when treated with nelarabine.
Hepatic Impairment
Nelarabine has not been studied in patients with hepatic impairment. These patients should be treated with caution.
Method of administration
Nelarabine is not diluted prior to administration. The appropriate dose of nelarabine is transferred into polyvinylchloride (PVC) or ethyl vinyl acetate (EVA) infusion bags or glass containers and administered as a two-hour infusion in adult patients and as a one-hour infusion in paediatric patients.
Complete blood counts including platelets must be monitored regularly (see sections 4.4 and 4.8).
*********************************************************
4.4 Special warnings and precautions for use
Sodium warning
This medicinal product contains 1.725 mg/ml (75 micromols) of sodium. To be taken into consideration by patients on a controlled sodium diet.
*********************************************************
4.6 Fertility, Ppregnancy and lactation
Contraception in males and females
Both sexually active men and women should use effective methods of contraception during treatment and for at least three months following cessation of treatment.
Pregnancy
There are no adequate data from the use of nelarabine in pregnant women.
Studies in animals have shown reproductive toxicity including malformations (see section 5.3). The potential risk in humans is unknown, however, exposure during pregnancy will likely lead to anomalies and malformations of the foetus.
Nelarabine should not be used during pregnancy unless clearly necessary. If a patient becomes pregnant during treatment with nelarabine, they should be informed of the possible risk to the foetus.
Breastfeeding
It is unknown whether nelarabine or its metabolites are excreted in human breast milk. The excretion of nelarabine in milk has not been studied in animals. However, because of the potential for serious adverse reactions in infants, breastfeeding should be discontinued.
Fertility
Both sexually active men and women should use effective methods of contraception during treatment and for at least three months following cessation of treatment.
The effect of nelarabine on fertility in humans is unknown. Based on the pharmacological action of the compound, undesirable effects on fertility are possible. Family planning should be discussed with patients as appropriate.
It is unknown whether nelarabine or its metabolites are excreted in human breast milk. The excretion of nelarabine in milk has not been studied in animals. However, because of the potential for serious adverse reactions in infants, breastfeeding should be discontinued.
*********************************************************
4.8 Undesirable effects
Clinical trial data
|
Adults (1,500 mg/m2) N=103(%) |
Children (650 mg/m2) N=84(%) |
Infections and infestations |
||
Infection (including but not limited to; sepsis, bacteraemia, pneumonia, fungal infection) |
Very common: 40 (39) |
Very common: 13 (15) |
Respiratory, thoracic, and mediastinal disorders |
||
Pleural effusion |
Common: 10 (10) |
N/A |
Wheezing |
Common: 5 (5) |
N/A |
Dyspnoea |
Very common: 21 (20) |
N/A |
Cough |
Very common: 26 (25) |
N/A |
|
*********************************************************
5. PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Adult studies
In an open-label study carried out by the Cancer and Leukaemia Group B and the Southwest Oncology Group, the safety and efficacy of nelarabine were evaluated in 39 adults with T-cell acute lymphoblastic leukaemia (T-ALL) or lymphoblastic lymphoma (T-LBL). Twenty–eight of the 39 adults had relapsed or were refractory to at least two prior induction regimens and aged between 16 to 65 years of age (mean 34 years). Nelarabine at a dose of 1500 mg/m2/day was administered intravenously over two hours on days 1, 3 and 5 of a 21 day cycle. Five of the 28 patients (18%) [95% CI:6%-37%] treated with nelarabine achieved a complete response (bone marrow blast counts ≤ 5%,no other evidence of disease, and full recovery of peripheral blood counts). A total of 6 patients (21%) [95% CI: 8%–41%] achieved a complete response with or without haematological recovery. Time to complete response in both classifications of response ranged from 2.9 to 11.7 weeks. Duration of response (in both classifications of response (n=5) ranged between 15 and 195+ weeks. Median overall survival was 20.6 weeks [95% CI: 10.4–36.4]. Survival at one year was 29% [95% CI: 12%–45%].
The European Medicines Agency (EMEA) will review any new information which may become available every year and this SPC will be updated as necessary.
*********************************************************
10. DATE OF REVISION OF THE TEXT
19 November 200829 November 2010
Detailed information on this medicinal product is available on the website of the European Medicine Agency (EMEA) http://www.emea.europa.eu/
Updated on 16 January 2009
Reasons for updating
- Change to section 4.2 - Posology and method of administration
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
4.2 Posology and method of administration
The following text has been added:
Nelaarbine is not diluted prior to administration. The appropriate dose of nelarabine is transferred into polyvinylchloride (PVC) or ethyl vinyl acetate (EVA) infusion bags or glass containers and administered as a two-hour infusion in adult patients and as a one-hour infusion in paediatric patients.
Updated on 26 August 2008
Reasons for updating
- Improved electronic presentation
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 6.3 of the SPC which changed the shelf life from 2years to 3years
Updated on 23 November 2007
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 05 October 2007
Reasons for updating
- New PIL for new product